|Grant Number:||3U24CA078142-05S4 Interpret this number|
|Primary Investigator:||Strong, Louise|
|Organization:||Ut Md Anderson Cancer Ctr|
|Project Title:||Texas Cancer Genetics Consortium|
DESCRIPTION: (Applicant's Description) We propose a Texas Cancer Genetics Consortium (TCGC) in response to the Cancer Genetics Network (CGN) RFA CA-97-004. This TCGC would bring to the CGN extensive expertise in basic and clinical cancer genetics, human and molecular genetics, management of confidential human cancer genetics data, community outreach in human genetics, professional and public education, and psychosocial studies of the impact of cancer genetic counseling and testing. The TCGC will include existing cancer high risk clinical populations, Ashkenazi Jewish populations, registries of familial breast, colon, MEN2, NF1 and other genetic susceptibility syndromes, many followed in studies for decades, patients at high cancer risk participating in screening and early detection studies or chemoprevention trials, and a large database of cancer patients from which to identify high risk family members for potential recruitment to the CGN. The Texas population is diverse in ethnic makeup, and the TCGC includes investigators with proven track records in assessing needs of the Hispanic and African American communities in health care, in providing health education to those communities and their healthcare providers, and in recruiting their participation in familial cancer registries and clinical and research studies. Funding of this application would provide the opportunity for our TCGC to strengthen our within consortium interactions, to contribute our research experience and expertise to the CGN design and implementation, and to utilize our experience and expertise in recruitment of high risk patients to CGN protocols. The long term goal is to contribute to the identification of cancer susceptibility genes, their mechanisms of action, frequency, penetrance, and genetic or environmental risk modifiers, to integrate this information into optimal patient management, and to assess needs and provide education to address the ethical and psychosocial concerns surrounding human cancer genetics.
Activating mutation in MET oncogene in familial colorectal cancer.
Authors: Neklason DW, Done MW, Sargent NR, Schwartz AG, Anton-Culver H, Griffin CA, Ahnen DJ, Schildkraut JM, Tomlinson GE, Strong LC, Miller AR, Stopfer JE, Burt RW
Source: BMC Cancer, 2011 Oct 4;11, p. 424.
EPub date: 2011 Oct 4.
Common familial colorectal cancer linked to chromosome 7q31: a genome-wide analysis.
Authors: Neklason DW, Kerber RA, Nilson DB, Anton-Culver H, Schwartz AG, Griffin CA, Lowery JT, Schildkraut JM, Evans JP, Tomlinson GE, Strong LC, Miller AR, Stopfer JE, Finkelstein DM, Nadkarni PM, Kasten CH, Mineau GP, Burt RW
Source: Cancer Res, 2008 Nov 1;68(21), p. 8993-7.
Design considerations in a sib-pair study of linkage for susceptibility loci in cancer.
Authors: Kerber RA, Amos CI, Yeap BY, Finkelstein DM, Thomas DC
Source: BMC Med Genet, 2008 Jul 10;9, p. 64.
EPub date: 2008 Jul 10.
Successful strategies for increasing African American participation in cancer genetic studies: hopeful signs for equalizing the benefits of genetic medicine.
Authors: Patterson AR, Davis H, Shelby K, McCoy J, Robinson LD, Rao SK, Banerji P, Tomlinson GE
Source: Community Genet, 2008;11(4), p. 208-14.
EPub date: 2008 Apr 14.
Assessing BRCA carrier probabilities in extended families.
Authors: Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI
Source: J Clin Oncol, 2006 Jan 20;24(3), p. 354-60.
Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6.
Authors: Hegde M, Blazo M, Chong B, Prior T, Richards C
Source: J Mol Diagn, 2005 Oct;7(4), p. 525-34.
Inherited susceptibility for pediatric cancer.
Authors: Plon SE, Nathanson K
Source: Cancer J, 2005 Jul-Aug;11(4), p. 255-67.
Recruitment for breast cancer predisposition studies in an underserved African American population.
Authors: Patterson A, Davis H, Euhus D, Neuhausen S, Strong L, Tomlinson G
Source: Breast J, 2005 Jan-Feb;11(1), p. 79-82.
Genotype-phenotype correlations in Peutz-Jeghers syndrome.
Authors: Amos CI, Keitheri-Cheteri MB, Sabripour M, Wei C, McGarrity TJ, Seldin MF, Nations L, Lynch PM, Fidder HH, Friedman E, Frazier ML
Source: J Med Genet, 2004 May;41(5), p. 327-33.
Limb girdle muscular dystrophy: use of dHPLC and direct sequencing to detect sarcoglycan gene mutations in a New Zealand cohort.
Authors: Love DR
Source: Clin Genet, 2004 Jan;65(1), p. 55-60.
Primary care physicians' attitudes and practices regarding cancer genetics: a comparison of 2001 with 1996 survey results.
Authors: Friedman L, Cooper HP, Webb JA, Weinberg AD, Plon SE
Source: J Cancer Educ, 2003 Summer;18(2), p. 91-4.
Re: On the use of familial aggregation in population-based case probands for calculating penetrance.
Authors: Amos CI
Source: J Natl Cancer Inst, 2003 Jan 1;95(1), p. 74-5; author reply 77-8.
Counseling the at risk patient in the BRCA1 and BRCA2 Era.
Authors: Barnes-Kedar IM, Plon SE
Source: Obstet Gynecol Clin North Am, 2002 Jun;29(2), p. 341-66, vii.
Detection of sequence variations in the adenomatous polyposis coli (APC) gene using denaturing high-performance liquid chromatography.
Authors: Wu G, Wu W, Hegde M, Fawkner M, Chong B, Love D, Su LK, Lynch P, Snow K, Richards CS
Source: Genet Test, 2001 Winter;5(4), p. 281-90.
Mammography behavior after receiving a negative BRCA1 mutation test result in the Ashkenazim: a community-based study.
Authors: Plon SE, Peterson LE, Friedman LC, Richards CS
Source: Genet Med, 2000 Nov-Dec;2(6), p. 307-11.